Abstract
N6-Methyladenosine (m6A), the most prevalent internal modification in eukaryotic mRNA, has been extensively and increasingly studied over the past decade. Dysregulation of RNA m6A modification and its associated machinery, including writers, erasers and readers, is frequently observed in various cancer types, and the dysregulation profiles might serve as diagnostic, prognostic and/or predictive biomarkers. Dysregulated m6A modifiers have been shown to function as oncoproteins or tumour suppressors with essential roles in cancer initiation, progression, metastasis, metabolism, therapy resistance and immune evasion as well as in cancer stem cell self-renewal and the tumour microenvironment, highlighting the therapeutic potential of targeting the dysregulated m6A machinery for cancer treatment. In this Review, we discuss the mechanisms by which m6A modifiers determine the fate of target RNAs and thereby influence protein expression, molecular pathways and cell phenotypes. We also describe the state-of-the-art methodologies for mapping global m6A epitranscriptomes in cancer. We further summarize discoveries regarding the dysregulation of m6A modifiers and modifications in cancer, their pathological roles, and the underlying molecular mechanisms. Finally, we discuss m6A-related prognostic and predictive molecular biomarkers in cancer as well as the development of small-molecule inhibitors targeting oncogenic m6A modifiers and their activity in preclinical models.
Key points
-
Epitranscriptomics relates to the post-transcriptional regulation of RNAs involving >170 chemical modifications, constituting one of several regulatory layers controlling gene expression. N6-Methyladenosine (m6A) is a major epitranscriptomic modification that contributes to the dynamic regulation of every biological process.
-
m6A marks are reversibly added by writers and removed by erasers, and are recognized by readers; this machinery modulates RNA splicing, nuclear export, stability and translation to determine the fate of RNAs and thus ensure tight control over gene expression.
-
Advanced global characterization and mapping techniques that provide information on locus-specific changes in m6A modification are key to a deeper understanding of the wide-ranging roles of m6A in the regulation of gene expression.
-
Dysregulation of m6A modifiers (writers, erasers and readers) is common across cancer types and has essential roles in cancer initiation, progression, metastasis, metabolism, drug resistance and immune evasion as well as in the tumour microenvironment.
-
Aberrant expression of m6A modifiers in cancer has been associated with a poor prognosis, therapy resistance and impaired antitumour immunity, and might therefore provide biomarkers with independent predictive value for use in diagnosis, prognostication and treatment selection.
-
Preclinical data underscore the potential of small-molecule inhibitors of oncogenic m6A modifiers in the treatment of cancer, either alone or in combination with conventional chemotherapy or immunotherapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Huang, H., Weng, H. & Chen, J. m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell 37, 270–288 (2020).
Qing, Y., Su, R. & Chen, J. RNA modifications in hematopoietic malignancies: a new research frontier. Blood 138, 637–648 (2021).
Hsu, P. J. et al. Ythdc2 is an N6-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 27, 1115–1127 (2017).
Roundtree, I. A. et al. YTHDC1 mediates nuclear export of N6-methyladenosine methylated mRNAs. eLife 6, e31311 (2017).
Shi, H. et al. YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA. Cell Res. 27, 315–328 (2017).
Wang, X. et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 505, 117–120 (2014).
Wang, X. et al. N6-methyladenosine modulates messenger RNA translation efficiency. Cell 161, 1388–1399 (2015).
Xiao, W. et al. Nuclear m6A reader YTHDC1 regulates mRNA splicing. Mol. Cell 61, 507–519 (2016).
Huang, H. et al. Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally. Nature 567, 414–419 (2019).
Liu, J. et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat. Chem. Biol. 10, 93–95 (2014).
Wang, X. et al. Structural basis of N6-adenosine methylation by the METTL3-METTL14 complex. Nature 534, 575–578 (2016).
Ping, X. L. et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 24, 177–189 (2014).
Schwartz, S. et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5′ sites. Cell Rep. 8, 284–296 (2014).
Wen, J. et al. Zc3h13 regulates nuclear RNA m6A methylation and mouse embryonic stem cell self-renewal. Mol. Cell 69, 1028–1038.e6 (2018).
Yue, Y. et al. VIRMA mediates preferential m6A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 4, 10 (2018).
Knuckles, P. et al. Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m6A machinery component Wtap/Fl(2)d. Genes Dev. 32, 415–429 (2018).
Pendleton, K. E. et al. The U6 snRNA m6A methyltransferase METTL16 regulates SAM synthetase intron retention. Cell 169, 824–835.e14 (2017).
van Tran, N. et al. The human 18S rRNA m6A methyltransferase METTL5 is stabilized by TRMT112. Nucleic Acids Res. 47, 7719–7733 (2019).
Ma, H. et al. N6-Methyladenosine methyltransferase ZCCHC4 mediates ribosomal RNA methylation. Nat. Chem. Biol. 15, 88–94 (2019).
Wei, J. et al. Differential m6A, m6Am, and m1A demethylation mediated by FTO in the cell nucleus and cytoplasm. Mol. Cell 71, 973–985.e5 (2018).
Jia, G. et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. Biol. 7, 885–887 (2011).
Zheng, G. et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol. Cell 49, 18–29 (2013).
Huang, H. et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat. Cell Biol. 20, 285–295 (2018).
Weng, H. et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell 40, 1566–1582.e10 (2022).
Müller, S. et al. IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. Nucleic Acids Res. 47, 375–390 (2018).
Degrauwe, N. et al. The RNA binding protein IMP2 preserves glioblastoma stem cells by preventing let-7 target gene silencing. Cell Rep. 15, 1634–1647 (2016).
Ennajdaoui, H. et al. IGF2BP3 modulates the interaction of invasion-associated transcripts with RISC. Cell Rep. 15, 1876–1883 (2016).
Edupuganti, R. R. et al. N6-methyladenosine (m6A) recruits and repels proteins to regulate mRNA homeostasis. Nat. Struct. Mol. Biol. 24, 870–878 (2017).
Zhang, F. et al. Fragile X mental retardation protein modulates the stability of its m6A-marked messenger RNA targets. Hum. Mol. Genet. 27, 3936–3950 (2018).
Alarcon, C. R. et al. HNRNPA2B1 Is a mediator of m6A-dependent nuclear RNA processing events. Cell 162, 1299–1308 (2015).
Liu, N. et al. N6-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature 518, 560–564 (2015).
Liu, N. et al. N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. Nucleic Acids Res. 45, 6051–6063 (2017).
Arguello, A. E., DeLiberto, A. N. & Kleiner, R. E. RNA chemical proteomics reveals the N6-methyladenosine (m6A)-regulated protein-RNA interactome. J. Am. Chem. Soc. 139, 17249–17252 (2017).
Dominissini, D. et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 485, 201–206 (2012).
Ke, S. et al. m6A mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover. Genes. Dev. 31, 990–1006 (2017).
Barbieri, I. et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature 552, 126–131 (2017).
Bertero, A. et al. The SMAD2/3 interactome reveals that TGFβ controls m6A mRNA methylation in pluripotency. Nature 555, 256–259 (2018).
Fish, L. et al. Nuclear TARBP2 drives oncogenic dysregulation of RNA splicing and decay. Mol. Cell 75, 967–981.e9 (2019).
Hu, L. et al. m6A RNA modifications are measured at single-base resolution across the mammalian transcriptome. Nat. Biotechnol. 40, 1210–1219 (2022).
Liu, C. et al. Absolute quantification of single-base m6A methylation in the mammalian transcriptome using GLORI. Nat. Biotechnol. 41, 355–366 (2023).
Xiao, Y. L. et al. Transcriptome-wide profiling and quantification of N6-methyladenosine by enzyme-assisted adenosine deamination. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01587-6 (2023).
Meyer, K. D. et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell 149, 1635–1646 (2012).
Chen, K. et al. High-resolution N6-methyladenosine (m6A) map using photo-crosslinking-assisted m6A sequencing. Angew. Chem. Int. Ed. Engl. 54, 1587–1590 (2015).
Linder, B. et al. Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat. Methods 12, 767–772 (2015).
Ke, S. et al. A majority of m6A residues are in the last exons, allowing the potential for 3′ UTR regulation. Genes Dev. 29, 2037–2053 (2015).
Molinie, B. et al. m6A-LAIC-seq reveals the census and complexity of the m6A epitranscriptome. Nat. Methods 13, 692–698 (2016).
Koh, C. W. Q., Goh, Y. T. & Goh, W. S. S. Atlas of quantitative single-base-resolution N6-methyl-adenine methylomes. Nat. Commun. 10, 5636 (2019).
Dierks, D. et al. Multiplexed profiling facilitates robust m6A quantification at site, gene and sample resolution. Nat. Methods 18, 1060–1067 (2021).
Yin, R. et al. Differential m6A RNA landscapes across hematopoiesis reveal a role for IGF2BP2 in preserving hematopoietic stem cell function. Cell Stem Cell 29, 149–159.e7 (2022).
Schwartz, S. et al. High-resolution mapping reveals a conserved, widespread, dynamic mRNA methylation program in yeast meiosis. Cell 155, 1409–1421 (2013).
Garcia-Campos, M. A. et al. Deciphering the “m6A code” via antibody-independent quantitative profiling. Cell 178, 731–747.e16 (2019).
Zhang, Z. et al. Single-base mapping of m6A by an antibody-independent method. Sci. Adv. 5, eaax0250 (2019).
Wang, Y., Xiao, Y., Dong, S., Yu, Q. & Jia, G. Antibody-free enzyme-assisted chemical approach for detection of N6-methyladenosine. Nat. Chem. Biol. 16, 896–903 (2020).
Shu, X. et al. A metabolic labeling method detects m6A transcriptome-wide at single base resolution. Nat. Chem. Biol. 16, 887–895 (2020).
Meyer, K. D. DART-seq: an antibody-free method for global m6A detection. Nat. Methods 16, 1275–1280 (2019).
Pratanwanich, P. N. et al. Identification of differential RNA modifications from nanopore direct RNA sequencing with xPore. Nat. Biotechnol. 39, 1394–1402 (2021).
Deng, X. et al. RNA N6-methyladenosine modification in cancers: current status and perspectives. Cell Res. 28, 507–517 (2018).
Huang, H. L., Weng, H. Y., Deng, X. L. & Chen, J. J. RNA modifications in cancer: functions, mechanisms, and therapeutic implications. Annu. Rev. Cancer Biol. 4, 221–240 (2020).
Dong, S., Wu, Y., Liu, Y., Weng, H. & Huang, H. N6-methyladenosine steers RNA metabolism and regulation in cancer. Cancer Commun. 41, 538–559 (2021).
Zeng, C., Huang, W., Li, Y. & Weng, H. Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J. Hematol. Oncol. 13, 117 (2020).
Peng, W. et al. Upregulated METTL3 promotes metastasis of colorectal cancer via miR-1246/SPRED2/MAPK signaling pathway. J. Exp. Clin. Cancer Res. 38, 393 (2019).
Wang, Q. et al. METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut 69, 1193–1205 (2020).
Choe, J. et al. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature 561, 556–560 (2018).
Li, Y. et al. METTL3 acetylation impedes cancer metastasis via fine-tuning its nuclear and cytosolic functions. Nat. Commun. 13, 6350 (2022).
Chen, M. et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology 67, 2254–2270 (2018).
Xiong, J. et al. Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol. Cell 82, 1660–1677.e10 (2022).
Du, Y. et al. SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function. Nucleic Acids Res. 46, 5195–5208 (2018).
Vu, L. P. et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat. Med. 23, 1369–1376 (2017).
Yankova, E. et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 593, 597–601 (2021).
Lin, S., Choe, J., Du, P., Triboulet, R. & Gregory, R. I. The m6A methyltransferase METTL3 promotes translation in human cancer cells. Mol. Cell 62, 335–345 (2016).
Wei, X. et al. METTL3 preferentially enhances non-m6A translation of epigenetic factors and promotes tumourigenesis. Nat. Cell Biol. 24, 1278–1290 (2022).
Sorci, M. et al. METTL3 regulates WTAP protein homeostasis. Cell Death Dis. 9, 796 (2018).
Weng, H. et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification. Cell Stem Cell 22, 191–205.e9 (2018).
Wang, M. et al. Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer. Mol. Cancer 19, 130 (2020).
Zhou, H., Yin, K., Zhang, Y., Tian, J. & Wang, S. The RNA m6A writer METTL14 in cancers: roles, structures, and applications. Biochim. Biophys. Acta Rev. Cancer 1876, 188609 (2021).
Lang, F. et al. EBV epitranscriptome reprogramming by METTL14 is critical for viral-associated tumorigenesis. PLoS Pathog. 15, e1007796 (2019).
Bansal, H. et al. WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia 28, 1171–1174 (2014).
Hu, C. et al. miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway. Int. J. Biol. Sci. 16, 2853–2867 (2020).
Naren, D. et al. High Wilms’ tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates m6A methylation of MYC mRNA. J. Cancer Res. Clin. Oncol. 147, 33–47 (2021).
Chen, Y. et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol. Cancer 18, 127 (2019).
Lyu, Y. et al. HIF-1α regulated WTAP overexpression promoting the Warburg effect of ovarian cancer by m6A-dependent manner. J. Immunol. Res. 2022, 6130806 (2022).
Li, Z. X. et al. WTAP-mediated m6A modification of lncRNA DIAPH1-AS1 enhances its stability to facilitate nasopharyngeal carcinoma growth and metastasis. Cell Death Differ. 29, 1137–1151 (2022).
Villa, E. et al. mTORC1 stimulates cell growth through SAM synthesis and m6A mRNA-dependent control of protein synthesis. Mol. Cell 81, 2076–2093.e9 (2021).
Cho, S. et al. mTORC1 promotes cell growth via m6A-dependent mRNA degradation. Mol. Cell 81, 2064–2075.e8 (2021).
Zeng, X. et al. METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma. Nat. Cancer 3, 1088–1104 (2022).
Su, R. et al. METTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis. Nat. Cell Biol. 24, 205–216 (2022).
Wang, X. K. et al. METTL16 promotes cell proliferation by up-regulating cyclin D1 expression in gastric cancer. J. Cell Mol. Med. 25, 6602–6617 (2021).
Dai, Y. Z. et al. METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m6A-dependent manner. Cell Mol. Biol. Lett. 27, 41 (2022).
Han, L. et al. METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. Cell Stem Cell 30, 52–68.e13 (2023).
Li, Y., Su, R., Deng, X., Chen, Y. & Chen, J. FTO in cancer: functions, molecular mechanisms, and therapeutic implications. Trends Cancer 8, 598–614 (2022).
Weng, H., Huang, H. & Chen, J. RNA N6-methyladenosine modification in normal and malignant hematopoiesis. Adv. Exp. Med. Biol. 1143, 75–93 (2019).
Su, R. et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell 38, 79–96.e11 (2020).
Li, Z. et al. FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell 31, 127–141 (2017).
Qing, Y. et al. R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. Mol. Cell 81, 922–939.e9 (2021).
Su, R. et al. R-2HG exhibits anti-tumor activity by targeting FTO/m(6)A/MYC/CEBPA signaling. Cell 172, 90–105.e23 (2018).
Huang, Y. et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell 35, 677–691.e10 (2019).
Cui, Y. H. et al. Autophagy of the m6A mRNA demethylase FTO is impaired by low-level arsenic exposure to promote tumorigenesis. Nat. Commun. 12, 2183 (2021).
Yang, S. et al. m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat. Commun. 10, 2782 (2019).
Zhang, C. et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proc. Natl Acad. Sci. USA 113, E2047–E2056 (2016).
Zhang, S. et al. m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell 31, 591–606.e6 (2017).
Shen, C. et al. RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia. Cell Stem Cell 27, 64–80.e9 (2020).
Wang, J. et al. Leukemogenic chromatin alterations promote AML leukemia stem cells via a KDM4C-ALKBH5-AXL signaling axis. Cell Stem Cell 27, 81–97.e8 (2020).
Chen, G. et al. Hypoxia induces an endometrial cancer stem-like cell phenotype via HIF-dependent demethylation of SOX2 mRNA. Oncogenesis 9, 81 (2020).
Dong, F. et al. ALKBH5 facilitates hypoxia-induced paraspeckle assembly and IL8 secretion to generate an immunosuppressive tumor microenvironment. Cancer Res. 81, 5876–5888 (2021).
Paris, J. et al. Targeting the RNA m6A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. Cell Stem Cell 25, 137–148.e6 (2019).
Cheng, Y. et al. N6-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation. Cancer Cell 39, 958–972.e8 (2021).
Sheng, Y. et al. A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex-mediated DNA replication. Blood 138, 2838–2852 (2021).
Chen, Z. H. et al. Nuclear export of chimeric mRNAs depends on an lncRNA-triggered autoregulatory loop in blood malignancies. Cell Death Dis. 11, 566 (2020).
Li, Z. et al. Suppression of m6A reader Ythdf2 promotes hematopoietic stem cell expansion. Cell Res. 28, 904–917 (2018).
Yao, X. et al. YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis. Cell Death Dis. 13, 258 (2022).
Chang, G. et al. YTHDF3 induces the translation of m6A-enriched gene transcripts to promote breast cancer brain metastasis. Cancer Cell 38, 857–871.e7 (2020).
Dixit, D. et al. The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells. Cancer Discov. 11, 480–499 (2021).
Fang, R. et al. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat. Commun. 12, 177 (2021).
Zaccara, S. & Jaffrey, S. R. A unified model for the function of YTHDF proteins in regulating m6A-modified mRNA. Cell 181, 1582–1595.e18 (2020).
Lasman, L. et al. Context-dependent functional compensation between Ythdf m6A reader proteins. Genes Dev. 34, 1373–1391 (2020).
Kontur, C., Jeong, M., Cifuentes, D. & Giraldez, A. J. Ythdf m6A readers function redundantly during zebrafish development. Cell Rep. 33, 108598 (2020).
Ni, W. et al. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m6A reader YTHDF3. Mol. Cancer 18, 143 (2019).
Li, H. et al. Downregulation of microRNA-6125 promotes colorectal cancer growth through YTHDF2-dependent recognition of N6-methyladenosine-modified GSK3β. Clin. Transl. Med. 11, e602 (2021).
Wang, S. et al. N6-methyladenosine reader YTHDF1 promotes ARHGEF2 translation and RhoA signaling in colorectal cancer. Gastroenterology 162, 1183–1196 (2022).
Wang, Z. L. et al. Comprehensive genomic characterization of RNA-binding proteins across human cancers. Cell Rep. 22, 286–298 (2018).
Bell, J. L. et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol. Life Sci. 70, 2657–2675 (2013).
Ramesh-Kumar, D. & Guil, S. The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer. Semin. Cancer Biol. 86, 18–31 (2022).
Wallis, N. et al. Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells. RNA Biol. 19, 26–43 (2022).
Weidensdorfer, D. et al. Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs. RNA 15, 104–115 (2009).
Zhang, Y. et al. m6A modification-mediated CBX8 induction regulates stemness and chemosensitivity of colon cancer via upregulation of LGR5. Mol. Cancer 18, 185 (2019).
An, M. X. et al. BAG3 directly stabilizes Hexokinase 2 mRNA and promotes aerobic glycolysis in pancreatic cancer cells. J. Cell Biol. 216, 4091–4105 (2017).
Li, Z. et al. N6-methyladenosine regulates glycolysis of cancer cells through PDK4. Nat. Commun. 11, 2578 (2020).
Lu, S. et al. N6-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer. J. Hematol. Oncol. 14, 188 (2021).
Chen, R. X. et al. N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. Nat. Commun. 10, 4695 (2019).
Du, A. et al. M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. Mol. Cancer 21, 109 (2022).
Oliveira-Mateos, C. et al. The transcribed pseudogene RPSAP52 enhances the oncofetal HMGA2-IGF2BP2-RAS axis through LIN28B-dependent and independent let-7 inhibition. Nat. Commun. 10, 3979 (2019).
Li, B. et al. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat. Commun. 12, 295 (2021).
Jiang, F. et al. HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. J. Hematol. Oncol. 14, 54 (2021).
Liu, H. et al. Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression. Mol. Cancer 21, 74 (2022).
Ma, J. Z. et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N6-methyladenosine-dependent primary microRNA processing. Hepatology 65, 529–543 (2017).
Shi, Y., Zhuang, Y., Zhang, J., Chen, M. & Wu, S. METTL14 inhibits hepatocellular carcinoma metastasis through regulating EGFR/PI3K/AKT signaling pathway in an m6A-dependent manner. Cancer Manag. Res. 12, 13173–13184 (2020).
Liu, J. et al. m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat. Cell Biol. 20, 1074–1083 (2018).
Zhang, C. et al. Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma. Theranostics 11, 3676–3693 (2021).
Liu, T. et al. Methyltransferase-like 14 suppresses growth and metastasis of renal cell carcinoma by decreasing long noncoding RNA NEAT1. Cancer Sci. 113, 446–458 (2022).
Zhang, L., Luo, X. & Qiao, S. METTL14-mediated N6-methyladenosine modification of Pten mRNA inhibits tumour progression in clear-cell renal cell carcinoma. Br. J. Cancer 127, 30–42 (2022).
Chen, X. et al. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer. Mol. Cancer 19, 106 (2020).
Wang, H. et al. TCF4 and HuR mediated-METTL14 suppresses dissemination of colorectal cancer via N6-methyladenosine-dependent silencing of ARRDC4. Cell Death Dis. 13, 3 (2021).
Yang, X. et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol. Cancer 19, 46 (2020).
Gu, C. et al. Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1. Mol. Cancer 18, 168 (2019).
Guo, X. et al. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner. Mol. Cancer 19, 91 (2020).
Huang, R. et al. RNA m6A demethylase ALKBH5 protects against pancreatic ductal adenocarcinoma via targeting regulators of iron metabolism. Front. Cell Dev. Biol. 9, 724282 (2021).
Ma, L. et al. The essential roles of m6A RNA modification to stimulate ENO1-dependent glycolysis and tumorigenesis in lung adenocarcinoma. J. Exp. Clin. Cancer Res. 41, 36 (2022).
Jin, D. et al. m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC. Mol. Cancer 19, 40 (2020).
Chen, Y. et al. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1. Mol. Cancer 19, 123 (2020).
Yu, H. et al. ALKBH5 inhibited cell proliferation and sensitized bladder cancer cells to cisplatin by m6A-CK2alpha-mediated glycolysis. Mol. Ther. Nucleic Acids 23, 27–41 (2021).
Yuan, Y. et al. ALKBH5 suppresses tumor progression via an m6A-dependent epigenetic silencing of pre-miR-181b-1/YAP signaling axis in osteosarcoma. Cell Death Dis. 12, 60 (2021).
He, Y. et al. ALKBH5-mediated m6A demethylation of KCNK15-AS1 inhibits pancreatic cancer progression via regulating KCNK15 and PTEN/AKT signaling. Cell Death Dis. 12, 1121 (2021).
Tang, B. et al. m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling. Mol. Cancer 19, 3 (2020).
Liu, X. et al. SIRT1 Regulates N6-methyladenosine RNA modification in hepatocarcinogenesis by inducing RANBP2-dependent FTO SUMOylation. Hepatology 72, 2029–2050 (2020).
Liu, L. et al. CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma. Mol. Cancer 21, 149 (2022).
Huang, H. et al. FTO-Dependent N6-methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling. Cancer Res. 80, 3200–3214 (2020).
Huang, J. et al. FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner. J. Exp. Clin. Cancer Res. 41, 42 (2022).
Hou, J. et al. YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma. Mol. Cancer 18, 163 (2019).
Zhong, L. et al. YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett. 442, 252–261 (2019).
Wang, J. et al. Downregulation of m6A reader YTHDC2 promotes the proliferation and migration of malignant lung cells via CYLD/NF-κB pathway. Int. J. Biol. Sci. 17, 2633–2651 (2021).
Hou, Y. et al. YTHDC1-mediated augmentation of miR-30d in repressing pancreatic tumorigenesis via attenuation of RUNX1-induced transcriptional activation of Warburg effect. Cell Death Differ. 28, 3105–3124 (2021).
Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424–2433 (2010).
Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009).
Shen, C. et al. m6A-dependent glycolysis enhances colorectal cancer progression. Mol. Cancer 19, 72 (2020).
Wang, W. et al. METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding. Nat. Commun. 12, 3803 (2021).
Wang, Q. et al. N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification. Cell Death Dis. 11, 911 (2020).
Du, L. et al. USP48 is upregulated by Mettl14 to attenuate hepatocellular carcinoma via regulating SIRT6 stabilization. Cancer Res. 81, 3822–3834 (2021).
Lin, J. X. et al. m6A methylation mediates LHPP acetylation as a tumour aerobic glycolysis suppressor to improve the prognosis of gastric cancer. Cell Death Dis. 13, 463 (2022).
Liu, Y. et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metab. 33, 1221–1233.e11 (2021).
Liu, H. et al. ALKBH5-mediated m6A demethylation of GLUT4 mRNA promotes glycolysis and resistance to HER2-targeted therapy in breast cancer. Cancer Res. 82, 3974–3986 (2022).
Xiao, Y. et al. The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. Proc. Natl Acad. Sci. USA 117, 21441–21449 (2020).
Zuo, X. et al. M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. J. Hematol. Oncol. 13, 5 (2020).
Liu, P. et al. m6A-induced lncDBET promotes the malignant progression of bladder cancer through FABP5-mediated lipid metabolism. Theranostics 12, 6291–6307 (2022).
Sepich-Poore, C. et al. The METTL5-TRMT112 N6-methyladenosine methyltransferase complex regulates mRNA translation via 18S rRNA methylation. J. Biol. Chem. 298, 101590 (2022).
Wang, L. et al. NADP modulates RNA m6A methylation and adipogenesis via enhancing FTO activity. Nat. Chem. Biol. 16, 1394–1402 (2020).
Li, N. et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc. Natl Acad. Sci. USA 117, 20159–20170 (2020).
Qiu, X. et al. M6A demethylase ALKBH5 regulates PD-L1 expression and tumor immunoenvironment in intrahepatic cholangiocarcinoma. Cancer Res. 81, 4778–4793 (2021).
Liu, Y. et al. Allosteric regulation of IGF2BP1 as a novel strategy for the activation of tumor immune microenvironment. ACS Cent. Sci. 8, 1102–1115 (2022).
Bai, X. et al. Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells. J. Immunother. Cancer 10, e003663 (2022).
Li, H. B. et al. m6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature 548, 338–342 (2017).
Tong, J. et al. m6A mRNA methylation sustains Treg suppressive functions. Cell Res. 28, 253–256 (2018).
Yao, Y. et al. METTL3-dependent m6A modification programs T follicular helper cell differentiation. Nat. Commun. 12, 1333 (2021).
Zhou, J. et al. m6A demethylase ALKBH5 controls CD4+ T cell pathogenicity and promotes autoimmunity. Sci. Adv. 7, eabg0470 (2021).
Song, H. et al. METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells. Nat. Commun. 12, 5522 (2021).
Wang, H. et al. Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation. Nat. Commun. 10, 1898 (2019).
Yin, H. et al. RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming. Nat. Commun. 12, 1394 (2021).
Tong, J. et al. Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation. Sci. Adv. 7, eabd4742 (2021).
Dong, L. et al. The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. Cancer Cell 39, 945–957.e10 (2021).
Han, D. et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature 566, 270–274 (2019).
Liu, J. et al. CCR7 chemokine receptor-inducible lnc-Dpf3 restrains dendritic cell migration by inhibiting HIF-1α-mediated glycolysis. Immunity 50, 600–615.e15 (2019).
Ma, S. et al. The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity. J. Exp. Med. 218, e20210279 (2021).
Feinberg, A. P., Koldobskiy, M. A. & Gondor, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 17, 284–299 (2016).
Xiao, Q. et al. Mutant NPM1-regulated FTO-mediated m6A demethylation promotes leukemic cell survival via PDGFRB/ERK signaling axis. Front. Oncol. 12, 817584 (2022).
Wang, P., Doxtader, K. A. & Nam, Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol. Cell 63, 306–317 (2016).
Tang, Y. et al. m6A-Atlas: a comprehensive knowledgebase for unraveling the N6-methyladenosine (m6A) epitranscriptome. Nucleic Acids Res. 49, D134–D143 (2021).
Uddin, M. B. et al. An N6-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells. Biochem. Pharmacol. 160, 134–145 (2019).
Tian, J. et al. ANKLE1 N6-methyladenosine-related variant is associated with colorectal cancer risk by maintaining the genomic stability. Int. J. Cancer 146, 3281–3293 (2020).
Li, Q. et al. HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation. Signal. Transduct. Target. Ther. 6, 76 (2021).
Zhu, L. et al. Impaired autophagic degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in gastric cancer. Cell Death Dis. 10, 383 (2019).
Cai, X. et al. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer Lett. 415, 11–19 (2018).
Yang, Z. et al. MicroRNA-145 modulates N6-methyladenosine levels by targeting the 3′-untranslated mRNA region of the N6-methyladenosine binding YTH domain family 2 protein. J. Biol. Chem. 292, 3614–3623 (2017).
Scholler, E. et al. Interactions, localization, and phosphorylation of the m6A generating METTL3-METTL14-WTAP complex. RNA 24, 499–512 (2018).
Yu, F. et al. Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response. Nucleic Acids Res. 49, 5779–5797 (2021).
Zhang, J. et al. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nat. Commun. 10, 1858 (2019).
Xia, T. L. et al. N6-Methyladenosine-binding protein YTHDF1 suppresses EBV replication and promotes EBV RNA decay. EMBO Rep. 22, e50128 (2021).
Li, T. et al. Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts. Gut 72, 501–511 (2023).
Chen, H. et al. RNA N6-methyladenosine methyltransferase METTL3 facilitates colorectal cancer by activating the m6A-GLUT1-mTORC1 axis and is a therapeutic target. Gastroenterology 160, 1284–1300.e16 (2021).
Cai, C. et al. M6A “Writer” Gene METTL14: a favorable prognostic biomarker and correlated with immune infiltrates in rectal cancer. Front. Oncol. 11, 615296 (2021).
Yue, B. et al. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol. Cancer 18, 142 (2019).
Du, Y. et al. An m6A-related prognostic biomarker associated with the hepatocellular carcinoma immune microenvironment. Front. Pharmacol. 12, 707930 (2021).
Wang, H., Zhao, X. & Lu, Z. m6a RNA methylation regulators Act as potential prognostic biomarkers in lung adenocarcinoma. Front. Genet. 12, 622233 (2021).
Lin, S. et al. Prognosis analysis and validation of m6A signature and tumor immune microenvironment in glioma. Front. Oncol. 10, 541401 (2020).
Guan, K. et al. Expression status and prognostic value of m6A-associated genes in gastric cancer. J. Cancer 11, 3027–3040 (2020).
Xu, C., He, T., Shao, X., Gao, L. & Cao, L. m6A-related lncRNAs are potential biomarkers for the prognosis of COAD patients. Front. Oncol. 12, 920023 (2022).
Tu, Z. et al. N6-Methylandenosine-related lncRNAs are potential biomarkers for predicting the overall survival of lower-grade glioma patients. Front. Cell Dev. Biol. 8, 642 (2020).
Lv, W. et al. Identification and validation of m6A-related lncRNA signature as potential predictive biomarkers in breast cancer. Front. Oncol. 11, 745719 (2021).
Zhang, B. et al. m6A target microRNAs in serum for cancer detection. Mol. Cancer 20, 170 (2021).
Xu, X. et al. METTL3-mediated m6A mRNA contributes to the resistance of carbon-ion radiotherapy in non-small-cell lung cancer. Cancer Sci. 114, 105–114 (2023).
Visvanathan, A. et al. Essential role of METTL3-mediated m6A modification in glioma stem-like cells maintenance and radioresistance. Oncogene 37, 522–533 (2018).
Wu, P. et al. N6-methyladenosine modification of circCUX1 confers radioresistance of hypopharyngeal squamous cell carcinoma through caspase1 pathway. Cell Death Dis. 12, 298 (2021).
Zhou, S. et al. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting beta-catenin through mRNA demethylation. Mol. Carcinog. 57, 590–597 (2018).
Kowalski-Chauvel, A. et al. The m6A RNA demethylase ALKBH5 promotes radioresistance and invasion capability of glioma stem cells. Cancers 13, 40 (2020).
Zhang, K. et al. N6-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming. Theranostics 12, 4802–4817 (2022).
Taketo, K. et al. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int. J. Oncol. 52, 621–629 (2018).
Wen, L., Pan, X., Yu, Y. & Yang, B. Down-regulation of FTO promotes proliferation and migration, and protects bladder cancer cells from cisplatin-induced cytotoxicity. BMC Urol. 20, 39 (2020).
Zhang, Z. et al. m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer. J. Hematol. Oncol. 14, 190 (2021).
Zhang, Z. et al. m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer. BMC Med. 19, 284 (2021).
Cai, Z. et al. Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas. Ann. Transl. Med. 9, 1241 (2021).
Wang, X. et al. The prognostic value and multiomic features of m6A-related risk signature in lung adenocarcinoma. Am. J. Transl. Res. 14, 5379–5393 (2022).
Yan, F. et al. A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res. 28, 1062–1076 (2018).
Bhattarai, P. Y., Kim, G., Poudel, M., Lim, S. C. & Choi, H. S. METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translation. Cancer Lett. 522, 44–56 (2021).
Fukumoto, T. et al. N(6)-Methylation of adenosine of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Res. 79, 2812–2820 (2019).
Li, X., Ma, S., Deng, Y., Yi, P. & Yu, J. Targeting the RNA m6A modification for cancer immunotherapy. Mol. Cancer 21, 76 (2022).
Zou, C., He, Q., Feng, Y., Chen, M. & Zhang, D. A m6Avalue predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response. NAR Cancer 4, zcac010 (2022).
Zhang, Z. et al. m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer. BMC Med. 19, 284 (2021).
Yu, M. et al. Comprehensive evaluation of the m6A regulator prognostic risk score in the prediction of immunotherapy response in clear cell renal cell carcinoma. Front. Immunol. 13, 818120 (2022).
Wang, L. et al. m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 39, e104514 (2020).
Han, Z. et al. Crystal structure of the FTO protein reveals basis for its substrate specificity. Nature 464, 1205–1209 (2010).
Zhou, L. L., Xu, H., Huang, Y. & Yang, C. G. Targeting the RNA demethylase FTO for cancer therapy. RSC Chem. Biol. 2, 1352–1369 (2021).
Chen, B. et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. J. Am. Chem. Soc. 134, 17963–17971 (2012).
Huang, Y. et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 43, 373–384 (2015).
Cui, Q. et al. m6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep. 18, 2622–2634 (2017).
Xiao, L. et al. FTO inhibition enhances the antitumor effect of temozolomide by targeting MYC-miR-155/23a cluster-MXI1 feedback circuit in glioma. Cancer Res. 80, 3945–3958 (2020).
Dong, L. et al. Relaxed initiation pausing of ribosomes drives oncogenic translation. Sci. Adv. 7, eabd6927 (2021).
Huff, S., Tiwari, S. K., Gonzalez, G. M., Wang, Y. & Rana, T. M. m6A-RNA demethylase FTO inhibitors impair self-renewal in glioblastoma stem cells. ACS Chem. Biol. 16, 324–333 (2021).
Huff, S. et al. Rational design and optimization of m6A-RNA demethylase FTO inhibitors as anticancer agents. J. Med. Chem. 65, 10920–10937 (2022).
Zheng, G. et al. Synthesis of a FTO inhibitor with anticonvulsant activity. ACS Chem. Neurosci. 5, 658–665 (2014).
Singh, B. et al. Important role of FTO in the survival of rare panresistant triple-negative inflammatory breast cancer cells facing a severe metabolic challenge. PLoS ONE 11, e0159072 (2016).
Fang, Z. et al. Discovery of a potent, selective and cell active inhibitor of m6A demethylase ALKBH5. Eur. J. Med. Chem. 238, 114446 (2022).
Selberg, S., Seli, N., Kankuri, E. & Karelson, M. Rational design of novel anticancer small-molecule RNA m6A demethylase ALKBH5 inhibitors. ACS Omega 6, 13310–13320 (2021).
Malacrida, A. et al. 3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line. Bioorg. Med. Chem. 28, 115300 (2020).
Bedi, R. K. et al. Small-molecule inhibitors of METTL3, the major human epitranscriptomic writer. ChemMedChem 15, 744–748 (2020).
Moroz-Omori, E. V. et al. METTL3 inhibitors for epitranscriptomic modulation of cellular processes. ChemMedChem 16, 3035–3043 (2021).
Dolbois, A. et al. 1,4,9-Triazaspiro[5.5]undecan-2-one derivatives as potent and selective METTL3 inhibitors. J. Med. Chem. 64, 12738–12760 (2021).
Mahapatra, L., Andruska, N., Mao, C., Le, J. & Shapiro, D. J. A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation. Transl. Oncol. 10, 818–827 (2017).
Feng, P. et al. Inhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia. Leukemia 36, 2180–2188 (2022).
Liu, J. et al. N6-Methyladenosine of chromosome-associated regulatory RNA regulates chromatin state and transcription. Science 367, 580–586 (2020).
Wei, J. et al. FTO mediates LINE1 m6A demethylation and chromatin regulation in mESCs and mouse development. Science 376, 968–973 (2022).
Acknowledgements
The work of the authors is partly supported by the US National Institutes of Health (NIH) grants R01 CA271497 and R01 CA 243386 (to J.C.), and a grant from the National Natural Science Foundation of China (82173058, to H.H.). We apologize to the researchers whose work could not be cited owing to space constraints.
Author information
Authors and Affiliations
Contributions
J.C. researched data for the article and organized the content. X.D., H.H. and J.C. made substantial contributions to the discussion of content. X.D., Y.Q., H.H. and J.C. wrote the manuscript. All the authors reviewed and edited the manuscript before submission.
Corresponding authors
Ethics declarations
Competing interests
J.C. is a scientific advisory board member of Race Oncology. The other authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Clinical Oncology thanks Stefan Hüttelmaier and the other, anonymous, reviewers for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Deng, X., Qing, Y., Horne, D. et al. The roles and implications of RNA m6A modification in cancer. Nat Rev Clin Oncol 20, 507–526 (2023). https://doi.org/10.1038/s41571-023-00774-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00774-x
This article is cited by
-
Writers, readers, and erasers RNA modifications and drug resistance in cancer
Molecular Cancer (2024)
-
The role of RNA methylation in tumor immunity and its potential in immunotherapy
Molecular Cancer (2024)
-
Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer
Journal of Translational Medicine (2024)
-
Reading the m6A-encoded epitranscriptomic information in development and diseases
Cell & Bioscience (2024)
-
YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment
Molecular Cancer (2024)
